Etanercept

Patients with rheumatoid arthritis who have lower disease activity are more likely to remain in remission after switching from combination therapy to monotherapy, according to data published in The Journal of Rheumatology.

What concept represents the most important and transformational article ever written in all of rheumatology?

Patients with rheumatoid arthritis who receive an etanercept biosimilar demonstrate similar disease activity and survival outcomes as those who receive the originator product, according to data published in Rheumatology.

Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.

In patients with non-radiographic axial spondyloarthritis who achieved inactive disease with etanercept, approximately 25% remained flare-free at 40 weeks after ceasing treatment, according to data published in the Journal of Rheumatology.

Etanercept and adalimumab are both impactful at improving the health of patients with non-systemic juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

PHILADELPHIA — The efficacy of COVID-19 vaccinations is similar in patients with psoriatic disease compared non-psoriatic controls, according to data presented at ACR Convergence 2022.

The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis.

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.

Etanercept was associated with reduced drug survival rates compared with other biologic therapies used to treat hidradenitis suppurativa, according to a study.